- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04573634
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition (START)
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition (START) - Assessment of COVID19 Penetrance in HCW and Non HCW in Kentucky
The co-primary objectives of this study are to:
- Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection
- Determine if PCR negativity for COVID-19 early in quarantine predicts negativity at Day 14 in quarantining individuals
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a prospective cohort study designed to identify the prevalence of IgG antibodies to SARS CoV-2 as well as to assess risk factors for IgG positivity. It will compare rates of positivity and risk factors among healthcare workers and non-healthcare workers and assess the ability of PCR negativity at day 3 or 4, 5, 7, or 10 to predict negativity on day 14 in individuals quarantining after a COVID exposure.
In addition to having a standard of care clinical antibody test, both healthcare workers, quarantining individuals, and patients will be asked to fill out a survey to assess risk factors for COVID infection and provide a research blood sample. Quarantining individuals will also have standard of care PCR testing on days 3 or 4, 5, 7, 10, and 14 of the quarantine period.
Collected blood samples will be used to assess for the presence of neutralizing antibodies and measure antibodies with a research test. An annual blood specimen and survey will be collected from each study participant for up to 2 years total after study entry.
Studietype
Kontakter og plasseringer
Studiesteder
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Individuals (health-care workers and patients) undergoing standard of care assessment of SARS-CoV-2 serology testing
- Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
- Able to understand and sign the Informed Consent and Research Authorization From.
Exclusion Criteria:
- Prisoners
- Patients with psychiatric illness that would limit compliance
- Patients with social situations that would limit compliance
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Health Care Workers
Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
|
Eligible Patients
Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
|
Quarantining Individuals
Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Prevalence of COVID-19
Tidsramme: 2 years
|
Proportion of people with IgG antibodies against SARS CoV-2 using a standard of care, Clinical Laboratory Improvement Amendments (CLIA), IgG antibody test.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
PCR Conversion in Exposed Individuals
Tidsramme: 14 days
|
Determine the average time point at which PCR conversion occurs following exposure.
|
14 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Jill Kolesar, PharmD, MS, University of Kentucky
- Hovedetterforsker: Derek Forster, MD, University of Kentucky
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PHARM-20-COVID19-START
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
HealthQuiltFullførtImmunfunksjon | Covid19 positiv pasient | Covid19 nærkontaktForente stater
-
VA Office of Research and DevelopmentAktiv, ikke rekrutterendeKOLS-pasienter og pasienter som kommer seg etter COVID19Forente stater
-
Bahçeşehir UniversityFullførtLang Covid19 | Autonom dysfunksjonTyrkia
-
Ohio State UniversityRekrutteringPost-akutt COVID19-syndrom | Lang COVID | Tilstand etter COVID19Forente stater
-
Texas Woman's UniversityNational Institutes of Health (NIH)Har ikke rekruttert ennå
-
Aarhus University HospitalUniversity of Aarhus; Pharma NordFullført
-
Cairo UniversityKasr El Aini HospitalUkjentCOVID19 lungebetennelseEgypt
-
Assistance Publique - Hôpitaux de ParisUkjent
-
Brugmann University HospitalRekruttering
-
North Carolina Central UniversityLumbee Tribe of North Carolina; University of North Carolina at PembrokeRekrutteringCovid19 virusinfeksjonForente stater